Company / Capital Returned to Shareholders
Viridian Therapeutics, Inc.\DE Capital Returned to Shareholders History
FY2016-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$2.0K
FY2016
5-year range
-
FY2016-FY2016
Trend
-
vs FY2015
Sector context
#47 of 52
Health Care
What the data says
Among 52 Health Care companies, Viridian Therapeutics, Inc.\DE is in the bottom 10% for capital returned to shareholders.
Based on SEC 10-K filings.
$2,000 in FY2016.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 52This company $2.0K Sector average $1.3B
▼
-100.0% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $2.0K | - |
As of FY2016 · SEC 10-K · Updated Jun 30, 2026